Clinical Trials Logo

Clinical Trial Summary

This is a prospective randomized open-label cross-over study. Poor responder patients will undergo two ovarian stimulation cycles. One with recombinant follicle stimulation hormone (FSH), and an other stimulation with recombinant FSH and recombinant luteinizing hormone (LH). In both groups, a freeze-all strategy will be applied and an endometrial biopsy will be taken 7 days after final oocyte maturation trigger. Endometrial gene expression analysis will be performed on both biopsies. After completion of both treatment cycles, a frozen embryo transfer of a single embryo will be performed.


Clinical Trial Description

This is a prospective randomized open-label cross-over study, in which patients will be randomized to either start in the control group or in the study group. Participants will undergo both treatments with an interval of minimum 1 and maximum 6 months. In both treatment arms, ovarian stimulation will be started at day 2/3 of the menstrual cycle. In the control group, 225 IU of recombinant FSH will be administered in a fixed antagonist protocol. In the study group, 225 IU of recombinant FSH plus 112,5 IU of recombinant LH will be administered. Cycle monitoring will be performed through serum estradiol (E2), progesterone (P), and luteinizing hormone (LH) assessments, combined with serial ultrasound examinations. Both groups will undergo dual triggering with gonadotropin releasing hormone agonist (GnRHa) 0,2ml and human chorionic gonadotrophin (hCG) 6500IU if one or more follicles of ≥ 17 mm are observed. The oocyte retrieval (OR) will be performed between 34 and 36 hours after final oocyte maturation trigger. At each OR, follicles will be individually meas-ured, aspirated and searched for the presence of cumulus oocyte complexes (COC). Metaphase II (MII) oocytes will then be injected to standard intra-cytoplasmatic sperm injection (ICSI) procedures. In both groups, a freeze-all strategy will be applied. An endometrial biopsy (Pipelle de Cornier ®) will be taken 7 days after final oocyte maturation trigger. After completion of both treatment cycles, a frozen embryo transfer of a single embryo will be performed. ;


Study Design


Related Conditions & MeSH terms

  • Poor Response to Ovulation Induction

NCT number NCT05405686
Study type Interventional
Source CRG UZ Brussel
Contact
Status Withdrawn
Phase Phase 4
Start date May 1, 2023
Completion date August 1, 2024

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05298657 - The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment
Suspended NCT04066478 - Does DHEA IVF Outcomes in Poor Responders? Phase 2/Phase 3
Recruiting NCT05181748 - Autologous Platelet Rich Plasma Intraovarian Infusion for Poor Responders Phase 2/Phase 3
Recruiting NCT04485819 - Optimal Embryonic Stage for Transfer in Poor Responders
Completed NCT05109403 - Ovarian Response in Oocyte Donors Triggered With GnRH Agonists
Recruiting NCT05780632 - A Prospective Observational Study of Biomarkers for a Personalised IVF Treatment